SUPN

#1826
Supernus Pharmaceuticals, Inc. - Common Stock
44.0 7 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
43.67
44.13
Jahresspanne
42.45
59.68
Tagesänderung
+0.75%
Monatliche Änderung
-12.65%
6 month change
-18.79%
Jahresänderung
-18.39%
Vorheriger Schlusskurs
43.7 4
Open
44.0 1
Tief
43.6 7
Hoch
44.1 3
Volumen
387
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 29 September 2020

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on September 29, 2020, with the report date finalized on October 5, 2020. The filing primarily addresses significant changes in executive leadership within the finance department.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.

Material Changes

  • Departure of CFO: Gregory S. Patrick, Senior Vice-President and Chief Financial Officer, notified the Company of his retirement effective on or about November 20, 2020. He will continue serving in his role until that date to ensure a transition.
  • Appointment of New CFO: James P. Kelly was appointed Executive Vice-President and Chief Financial Officer, effective October 12, 2020.
  • Compensation Package for New CFO:
    • Annual base salary: $460,000.
    • Target annual bonus: Up to 45% of base salary (prorated for the first year).
    • Equity: 135,000 stock options vesting over four years.
  • Retention Agreement: Mr. Kelly entered into an Executive Retention Agreement providing for 12 months of base salary and health benefits upon termination without cause or for good reason. In the event of a change in control, the agreement includes a lump-sum bonus payment and full vesting of stock-based compensation.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the transition of the Chief Financial Officer role, which the Company states is being managed to ensure efficiency. The Retention Agreement is subject to the Company's clawback policy.

Investor Verification Checklist

  • Verify the exact effective date of Gregory S. Patrick's retirement (stated as "on or about November 20, 2020").
  • Review the full text of the Executive Retention Agreement (Exhibit 10.2) for specific definitions of "cause" and "good reason."
  • Confirm the vesting schedule and exercise terms for the 135,000 stock options granted to James P. Kelly under the 2012 Equity Incentive Plan.
  • Monitor subsequent filings for the official departure of the former CFO and the commencement of the new CFO's tenure.

Nachrichten